Keyword Analysis & Research: mogamulizumab


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
mogamulizumab0.390.956756913

Keyword Research: People who searched mogamulizumab also searched

Keyword CPC PCC Volume Score
mogamulizumab0.670.485667

Search Results related to mogamulizumab on Search Engine

  • Mogamulizumab - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/Mogamulizumab

    WEBMogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4). The U.S. Food and Drug Administration (FDA) approved it in August 2018 for treatment of relapsed or refractory mycosis fungoides and Sézary disease.

    DA: 69 PA: 26 MOZ Rank: 65

  • Mogamulizumab Uses, Side Effects & Warnings - Drugs.com

    drugs.com

    https://www.drugs.com/mtm/mogamulizumab.html

    WEBNov 6, 2023 · What is mogamulizumab? Mogamulizumab is used to treat mycosis fungoides or Sézary syndrome in adults. Mogamulizumab is given after at least one other medication did not work or has stopped working. Mogamulizumab may also be used for purposes not listed in this medication guide.

    DA: 7 PA: 82 MOZ Rank: 53

  • Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369856/

    WEBFeb 7, 2019 · The approval of mogamulizumab, a humanized, glycoengineered IgG1κ monoclonal antibody targeting the chemokine receptor type 4 (CCR4) chemokine receptor, brings a novel tool into the spectrum of treatment options for advanced CTCL and adult T-cell leukemia/lymphoma (ATLL).

    DA: 14 PA: 45 MOZ Rank: 51

  • Pharmacoeconomic Review - Mogamulizumab (Poteligeo) - NCBI …

    nih.gov

    https://www.ncbi.nlm.nih.gov/books/NBK602686/

    WEBOverview. The proposed indication for mogamulizumab is for the treatment of mycosis fungoides or Sézary syndrome among adults who have received at least 1 prior systemic treatment. 2 The sponsor submitted a cost-utility analysis of mogamulizumab compared with ECM, which was conceptualized as a basket of treatments (). 1 The modelled …

    DA: 98 PA: 7 MOZ Rank: 63

  • Mogamulizumab | Memorial Sloan Kettering Cancer Center

    mskcc.org

    https://www.mskcc.org/cancer-care/patient-education/medications/adult/mogamulizumab

    WEBDec 12, 2022 · Mogamulizumab. Adult Medication. This information from Lexicomp ® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US. Poteligeo. What is this drug used for? It is used to treat a type of lymphoma that affects …

    DA: 86 PA: 24 MOZ Rank: 77


  • Mogamulizumab-kpkc - NCI - National Cancer Institute

    cancer.gov

    https://www.cancer.gov/about-cancer/treatment/drugs/mogamulizumabkpkc

    WEBMogamulizumab-kpkc is approved to treat: Mycosis fungoides or Sezary syndrome (types of cutaneous T-cell lymphoma). It is used to treat disease that has relapsed (come back) or is refractory (does not respond to treatment) in adult patients who have received at least one other type of systemic therapy.

    DA: 26 PA: 93 MOZ Rank: 4

  • Mogamulizumab: Uses, Interactions, Mechanism of Action

    drugbank.com

    https://go.drugbank.com/drugs/DB12498

    WEBOct 20, 2016 · Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma.

    DA: 10 PA: 56 MOZ Rank: 90

  • Mogamulizumab for adult T-cell leukemia-lymphoma: a …

    ashpublications.org

    https://ashpublications.org/bloodadvances/article/4/20/5133/469704/Mogamulizumab-for-adult-T-cell-leukemia-lymphoma-a

    WEBOct 22, 2020 · Abstract. Monitoring of Immune Responses Following Mogamulizumab-Containing Treatment in Patients with Adult T-Cell Leukemia-Lymphoma (ATL) (MIMOGA) is a multicenter prospective observational study to establish the most effective and safe treatment strategy using mogamulizumab for ATL patients (UMIN000008696).

    DA: 54 PA: 86 MOZ Rank: 13

  • FDA approves mogamulizumab-kpkc for mycosis fungoides or …

    fda.gov

    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mogamulizumab-kpkc-mycosis-fungoides-or-sezary-syndrome

    WEBOn Aug. 8, 2018, the Food and Drug Administration approved mogamulizumab-kpkc (Poteligeo, Kyowa Kirin, Inc.) for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary...

    DA: 65 PA: 12 MOZ Rank: 26

  • Safety and efficacy profile of mogamulizumab (Poteligeo) in the

    biomedcentral.com

    https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08363-w

    WEBMay 26, 2021 · Mogamulizumab is a humanized, IgG1 kappa monoclonal antibody that is directed against CCR4. By reducing the number of CCR4-positive Tregs and tumor cells, the mogamulizumab can reduce tumor burden and boost antitumor immunity to achieve antitumor effects. Methods. We examined the PubMed and ClinicalTrials.gov until 1 …

    DA: 27 PA: 35 MOZ Rank: 78